Author/Authors :
Sanei, Mohammad Hossein Isfahan University of Medical Sciences, Isfahan , Mirmosayyeb, Omid Students’ Research Committee- Isfahan University of Medical Sciences, Isfahan , Chehrei, Ali Pars Medical Laboratory- Arak University of Medical Sciences, Arak , Ansari, Jamshid Dept. of Radiotherapy- Arak University of Medical Sciences, Arak , Saberi, Elahe Isfahan University of Medical Sciences, Isfahan
Abstract :
Background & Objective: Gastric cancer is the second most frequent cause of cancer
death worldwide, despite differences in incidence around the world. The majority of
gastric cancer cases concern gastric adenocarcinoma, which has a fairly high 5-year
survival rate when coupled with early-stage diagnosis. Versican, a member of the aggregating
chondroitin sulfate proteoglycans family, is accumulated predominantly in
the tumor stroma. The aim of our study was to investigate versican expression in
gastric adenocarcinoma.
Methods: In this study we investigated 80 patients with gastric adenocarcinoma who
underwent gastrectomy. Each sample was obtained from paraffin-embedded resected
specimens of the stomach after histopathological diagnosis. Patient follow-up was
performed every 3 months after the beginning of data collection. Survival analysis
was calculated using the Kaplan-Meier method for univariate analysis.
Results: Out of 80 patients with gastric adenocarcinoma, 76 cases (76.3%males and
23.7% females) completed the follow-up period. Positive versican expression in tumor
epithelial and stromal cells was found in 39.5% and 22.4% of tumors, respectively.
Shorter survival was observed among patients whose gastric adenocarcinoma
expressed epithelial or stromal versican.
Conclusion: In summary, the present study suggests that versican is likely a prognostic
biomarker that predicts a poor outcome in patients with gastric adenocarcinoma.
Comprehensive studies with larger sample sizes are needed.
